| Literature DB >> 27739690 |
Melania Olivieri1, Emanuele Amata2, Shila Vinciguerra2, Jole Fiorito2, Giovanni Giurdanella1, Filippo Drago1, Nunzia Caporarello1, Orazio Prezzavento2, Emanuela Arena2, Loredana Salerno2, Antonio Rescifina2, Gabriella Lupo1, Carmelina Daniela Anfuso1, Agostino Marrazzo2.
Abstract
(±)-MRJF22 [(±)-2], a novel prodrug of haloperidol metabolite II (sigma-1 receptor antagonist/sigma-2 receptor agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an ester bond, exhibits antiangiogenic activity, being able to reduce human retinal endothelial cell (HREC) viability in a comparable manner to bevacizumab. Moreover, (±)-2 was able to significantly reduce viable cells count, endothelial cell migration, and tube formation in vascular endothelial growth factor A (VEGF-A) stimulated HREC cultures.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27739690 DOI: 10.1021/acs.jmedchem.6b01039
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446